The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
OBJECTIVE
The present study investigates the effects of serum CA-125 level and CA-125 tissue positivity on first-year recurrences in patients with stage III/IV epithelial ovarian tumors.


METHODS
Of the 101 patients with EOC who had undergone systematic pelvic/para-aortic lymphadenectomy between January 2003 and December 2007 recurrence did not develop in patients with stage I/II EOC. Fifty-five patients with FIGO stage III/IV EOC were evaluated in terms of serum CA-125 level and CA-125 tissue positivity. Preoperative CA-125 levels, under 35 IU/l were considered normal. To determine the expression of CA-125 immunohistochemically, stainings exceeding 10% were considered as positive.


RESULTS
The relationship between CA-125 values and recurrence was significant in stage III/IV patients (p = 0.041/p = 0.006). The relationship between CA-125 values and recurrence was significant in the patients with serous tumor, endometrioid tumor, clear cell tumor, and undifferentiated tumor (p = 0.034/p = 0.044/p = 0.039/p = 0.043 respectively, p < 0.05). It was insignificant in mucinous tumor (p = 0.667). The relationship between CA-125 tissue expression positivity and recurrence development was significant in stage III/IV patients (p = 0.041/p = 0.029). It was significantly correlated with recurrence in the patients with serous tumor, endometrioid tumor, clear cell tumor, mucinous tumor, and undifferentiated tumor (p = 0.034/p = 0.044/p = 0.047/p = 0.036/p = 0.043 respectively, p < 0.05).


CONCLUSIONS
We were able to show that serum CA-125 values and CA-125 tissue expression can be used as markers to predict the risk of early recurrence. Many factors play an important role in the prediction of early recurrences in advanced stage EOC.
Gundogdu
Fatih
F
2nd Obstetrics and Gynecology Clinic of Izmir, Ataturk Education and Research Hospital, Izmir, Turkey.
Soylu
Ferit
F
Erkan
Levent
L
Tatli
Orkan
O
Mavi
Sadiye
S
Yavuzcan
Ali
A
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D000077216:Carcinoma, Ovarian Epithelial; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008197:Lymph Node Excision; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D010053:Ovary / Q000473:pathology*; D011237:Predictive Value of Tests
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins